

National Institutes of Health**Advertisement of an Opportunity To Investigate the Effect of Nitroxide Compounds on Diseases Relating to Stresses of Aging**

AGENCY: National Institute on Aging, NIH.

ACTION: Advertisement of an opportunity.

SUMMARY: The National Institute on Aging is seeking a Cooperative Research and Development Agreement (CRADA) with a pharmaceutical company to investigate the effect of nitroxide compounds on diseases related to the stresses of aging.

The Collaborator must be able to collaborate with NIA staff to explore the effect nitroxides have on diseases of aging. The Collaborator must have a demonstrated record of success in privately producing nitroxide compounds suitable for pharmaceutical application, as well as a reputation for excellence in research.

The term of the CRADA will be up to five (5) years.

DATES: Interested parties should notify this office in writing of their intent to file a formal proposal no later than May 5, 1997. Formal proposals must be submitted to this office no later than June 3, 1997.

ADDRESSES: Inquiries and proposals regarding this opportunity should be addressed to Bruce D. Goldstein, J.D., (Tel. #301-496-0477, FAX # 301-402-2177), Office of Technology Development, National Center Institute, Executive Plaza South, Suite 450, 6120 Executive Blvd. MSC 7182, Bethesda, Maryland, 20892.

SUPPLEMENTARY INFORMATION: A CRADA is the anticipated joint agreement to be entered into by NIA pursuant to the Federal Technology Transfer Act of 1986, as amended by the National Technology Transfer Act (Pub. L. #104-1993 (1996)) and by Executive Order 12591 of October 10, 1987. NIA is presently exploring the protective effects of nitroxide compounds on oxyradical-induced oxidative stress, to the extent such stresses are related to diseases of aging.

- Under the present proposal, the goal of the CRADA will be research into, and development of, the following technology:

- Assessment of the qualitative and quantitative influence nitroxide compounds have on various aspects of the aging process.

- Development of new nitroxide compounds having *in vivo* inhibitive effect on the formation of oxyradicals.

- Development of new nitroxide compounds that enhance neuronal function and performance of aged animals.

Party Contributions

The role of NIA includes the following:

- (1) Provide staff, expertise, & materials for the development of the desired compounds;
- (2) Evaluate the work product of Collaborator to ensure progress toward meeting the CRADA goals; and
- (3) Provide work space, expertise, and equipment for production of any prototypes developed.

The role of the successful Collaborator will include the following:

- (1) Provide expertise on biological aging mechanisms and assistance in the development of nitroxide compounds likely to have therapeutic value;
- (2) Provide funding, as necessary, in support of production and dissemination of the desired compounds; and
- (3) Provide resources and expertise to market any products developed.

Selection Criteria

Proposals submitted for consideration should fully address each of the following qualifications:

- (1) Expertise:
 - (A) Demonstrated expertise in developing and producing nitroxide compounds;
 - (B) Demonstrated expertise on biological aging mechanisms;
 - (C) Demonstrated ability to secure national and international marketing and distribution of nitroxide compounds;
 - (D) Demonstrated expertise in overseeing all aspects of product development; and
 - (E) Demonstrated intellectual ability to participate in the research and commercial ability to guide development of the results into a viable product line.

(2) Physical Resources:

- (A) An established headquarters with offices, space, and equipment;
- (B) Access to the organization during business hours by telephone, mail, e-mail, the Internet, and other evolving technologies; and

- (C) Sufficient financial resources to support the current activities of the CRADA to meet the needs of NIA.

Dated: February 18, 1997.

Thomas D. Mays,

Director, Office of Technology Development, NCI, NIH.

[FR Doc. 97-5322 Filed 3-4-97; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: Subcommittee D—Clinical Research Studies Subcommittee.

Date: April 1-2, 1997.

Time: 8:00 am.

Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Martin H. Goldrosen, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, 6130 Executive Blvd. Room 635C, Bethesda, Md 20892, Telephone: 301-496-7930.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research. 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: February 27, 1997.

LaVerne Y. Springfield,

Committee Management Officer, NIH.

[FR Doc. 97-5319 Filed 3-4-97; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Investigator Grants for Clinical Center Therapy Research.

Date: March 24-26, 1997.

Time: 9:00 am.

Place: DoubleTree Hotel, Halpine Room, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Wilna A. Woods, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 605, 6130 Executive Boulevard, MSC 7410, Bethesda, MD 20892-7405, Telephone: 301/496-7903.

Purpose/Agenda: To evaluate and review grant applications.

The meeting will be closed in accordance with the provisions set forth in secs.